GraniteShares Advisors LLC Sells 155 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

GraniteShares Advisors LLC decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,110 shares of the biopharmaceutical company’s stock after selling 155 shares during the quarter. GraniteShares Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $570,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Fortitude Family Office LLC bought a new stake in Alnylam Pharmaceuticals during the first quarter worth $135,000. Bannerman Wealth Management Group LLC grew its holdings in Alnylam Pharmaceuticals by 96.2% during the first quarter. Bannerman Wealth Management Group LLC now owns 2,729 shares of the biopharmaceutical company’s stock worth $737,000 after buying an additional 1,338 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in Alnylam Pharmaceuticals by 114.7% during the first quarter. Handelsbanken Fonder AB now owns 116,683 shares of the biopharmaceutical company’s stock worth $31,507,000 after buying an additional 62,337 shares in the last quarter. SG Americas Securities LLC grew its holdings in Alnylam Pharmaceuticals by 7,876.0% during the first quarter. SG Americas Securities LLC now owns 132,960 shares of the biopharmaceutical company’s stock worth $35,902,000 after buying an additional 131,293 shares in the last quarter. Finally, Accurate Wealth Management LLC bought a new stake in Alnylam Pharmaceuticals during the first quarter worth $670,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $304.67 on Friday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 52-week low of $152.30 and a 52-week high of $310.22. The firm has a market cap of $39.73 billion, a price-to-earnings ratio of -140.40 and a beta of 0.22. The business’s fifty day moving average is $268.41 and its 200 day moving average is $258.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the firm posted ($0.16) EPS. The business’s revenue for the quarter was up 20.2% compared to the same quarter last year. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the business’s stock in a transaction on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the sale, the chief executive officer now directly owns 48,948 shares in the company, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ALNY shares. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a report on Friday, March 21st. Stifel Nicolaus upped their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Chardan Capital boosted their price objective on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Finally, Morgan Stanley cut their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a research report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $319.58.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.